The 3,533 adults from 387 sites in 28 countries, including the UK, who underwent randomisation 1,767 in the semaglutide group and 1,766 in the placebo group were followed up after a median of 3.4 years
Our Process Step 1 Virtual Consult Complete a comprehensive health assessment with one of our licensed medical providers
Ongoing progress monitoring Regular assessments to track body weight changes and overall response to the program
Based on the timeline, the earliest realistic FDA approval date is late 2025 or 2026
As the OD value of the standard curve may vary according to the conditions of the actual assay performance (e.g operator, pipetting technique or temperature effects), so the standard curve and data are provided as below for reference only
Retatrutide could potentially be the next big thing in weight loss therapy